Grove Bank & Trust’s Cogent Biosciences COGT Stock Holding History

Grove Bank & Trust’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-127	Closed	-$4.51K	–	863
2025 Q4	$4.51K	Buy	+127	New	+$3.57K	﹤0.01%	736

Other funds holding COGT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Grove Bank & Trust's COGT Position: Q1 2026 in Review

Grove Bank & Trust sold out of Cogent Biosciences (COGT) in Q1 2026, closing a stake of 127 shares — an estimated $4.51K sold.

Grove Bank & Trust first reported a position in COGT in Q4 2025 and held it in 1 quarter. The position peaked at $4.51K in Q4 2025. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

Grove Bank & Trust reported no remaining Cogent Biosciences position as of Q1 2026 after selling out during the quarter.
Grove Bank & Trust sold 127 Cogent Biosciences shares in Q1 2026, an estimated $4.51K.
Grove Bank & Trust first reported a position in Cogent Biosciences in Q4 2025 and held it in 1 quarter.
Grove Bank & Trust's Cogent Biosciences position peaked at $4.51K in Q4 2025.
305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on Grove Bank & Trust's 13F filing for Q1 2026, filed 8 Apr 2026.